4//SEC Filing
Farrow Jeffrey S 4
Accession 0001819790-25-000102
CIK 0001819790other
Filed
Jun 17, 8:00 PM ET
Accepted
Jun 18, 4:07 PM ET
Size
9.1 KB
Accession
0001819790-25-000102
Insider Transaction Report
Form 4
Farrow Jeffrey S
See Remarks
Transactions
- Sale
Common Stock
2025-06-17$40.42/sh−13,608$550,035→ 36,704 total - Exercise/Conversion
Common Stock
2025-06-16+27,881→ 50,312 total - Exercise/Conversion
Restricted Stock Units
2025-06-16−27,881→ 55,763 total→ Common Stock (27,881 underlying)
Footnotes (4)
- [F1]The shares were issued pursuant to settlement of vested Restricted Stock Units ("RSUs"). Each RSU represents a contingent right to receive one share of the Company's common stock.
- [F2]The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person.
- [F3]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Company's common stock.
- [F4]RSUs granted on April 24, 2023, under the Tarsus Pharmaceuticals, Inc. 2020 Stock Plan. 25% of the RSUs will vest on June 15th of each of 2024, 2025, 2026 and 2027, subject to the Reporting Person's continuous service.
Documents
Issuer
Tarsus Pharmaceuticals, Inc.
CIK 0001819790
Entity typeother
Related Parties
1- filerCIK 0001405253
Filing Metadata
- Form type
- 4
- Filed
- Jun 17, 8:00 PM ET
- Accepted
- Jun 18, 4:07 PM ET
- Size
- 9.1 KB